Announcements
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- ResMed Announces Participation in the RBCCM Global Healthcare Conference
- ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
- ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
More ▼
Key statistics
On Thursday, RESMED INC DRN (R1MD34:SAO) closed at 270.76, -4.33% below its 52-week high of 283.00, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 273.56 |
---|---|
High | 274.40 |
Low | 270.76 |
Bid | 270.48 |
Offer | 273.84 |
Previous close | 270.76 |
Average volume | 21.33 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 1.87 BRL |
---|---|
Annual div yield (ADY) | 0.69% |
Div ex-date | May 08 2024 |
Div pay-date | Jun 19 2024 |
Data delayed at least 15 minutes, as of May 23 2024 20:54 BST.
More ▼